Join the Crohn's Disease - Maintenance group to help and get support from people like you.
Crohn's Disease - Maintenance News (Page 2)
Study Compares Surgical Techniques for Crohn Disease
THURSDAY, Aug. 1, 2024 – For patients undergoing open or laparoscopic resection of the small bowel or strictureplasty for Crohn disease (CD), small bowel resection is associated with the longest...
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 – For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for endoscopic remission...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 – There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory bowel disease (IBD)...
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...
FDA Approves Ixifi (infliximab-qbtx), a Biosimilar to Remicade
December 13, 2017 – Pfizer Inc. (NYSE:PFE) announced today that the United States (U.S.) Food and Drug Administration (FDA) has approved Ixifi (PF-06438179, infliximab-qbtx), a chimeric...
FDA Approves Cyltezo (adalimumab-adbm), a Biosimilar to Humira
Ridgefield, Conn., August 29, 2017 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved Cyltezo, a biosimilar to Humira, in a p...
FDA Approves Renflexis (infliximab-abda), a Biosimilar to Remicade
INCHEON, Korea – April 24, 2017 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Renflexis (infliximab-abda), a biosimilar referencing Rem...
FDA Approves Amjevita (adalimumab-atto), a Biosimilar to Humira
September 23, 2016 – The U.S. Food and Drug Administration today approved Amjevita (adalimumab-atto) as a biosimilar to Humira (adalimumab) for multiple inflammatory diseases. Amjevita is approved...
Further information
Related condition support groups
Related drug support groups
metronidazole, Humira, Entyvio, adalimumab, budesonide, Cimzia